{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:23:54Z","timestamp":1786487034314,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>SAPHO syndrome is a rare chronic aseptic inflammatory disorder characterized by the concurrence of osteoarticular inflammation and cutaneous lesions. The intricate mechanism network, coupled with issues such as paradoxical reactions, often results in suboptimal therapeutic outcomes. To the best of our knowledge, this is the first report of refractory SAPHO syndrome achieving clinical remission with the combination of guselkumab (an IL-23 inhibitor) and upadacitinib (a JAK inhibitor). A 38-year-old male with refractory SAPHO experienced complete pain resolution within 2 weeks and significant improvement in cutaneous lesions by 4 weeks post-treatment, with a favorable safety profile observed throughout the follow-up period. We further analyzed the underlying inflammatory mechanisms to provide a therapeutic clues for the management of similar refractory cases.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1745464","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:41:12Z","timestamp":1771569672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful management of refractory SAPHO syndrome with guselkumab-upadacitinib combination"],"prefix":"10.3389","volume":"17","author":[{"given":"Di","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Yuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Graduate School, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ting","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Shanghai Children\u2019s Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-016-0583-y","article-title":"SAPHO syndrome: current developments and approaches to clinical treatment","volume":"18","author":"Firinu","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.05.016","article-title":"IL-23\/Th17 targeted therapies in SAPHO syndrome. A case series","volume":"84","author":"Wendling","year":"2017","journal-title":"Joint Bone Spine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427784","article-title":"The role of cytokines in the pathogenesis of SAPHO syndrome","volume":"15","author":"Yi","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/jcm14041366","article-title":"What is new and what is next for SAPHO syndrome management: A narrative review","volume":"14","author":"Ferraioli","year":"2025","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1662675","article-title":"Upadacitinib in the treatment of SAPHO syndrome: a case report","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/ar2837","article-title":"SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended","volume":"11","author":"Rozin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181393","article-title":"Copy number variation of multiple genes in SAPHO syndrome","volume":"47","author":"Schinocca","year":"2019","journal-title":"J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.04.003","article-title":"Biologics in SAPHO syndrome: A systematic review","volume":"48","author":"Daoussis","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201260","article-title":"Clinical and radiological remission of osteoarticular and cutaneous lesions in SAPHO patients treated with secukinumab: A case series","volume":"48","author":"Wang","year":"2021","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16492","article-title":"Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome associated with pyoderma gangrenosum: report of two patients","volume":"62","author":"Ma","year":"2022","journal-title":"Int J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105587","article-title":"Efficacy of baricitinib in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: A case series","volume":"90","author":"Liu","year":"2023","journal-title":"Joint Bone Spine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16071","article-title":"Successful treatment of SAPHO syndrome with apremilast","volume":"179","author":"Adamo","year":"2017","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.043","article-title":"Specific targeting of interleukin-23p19 as effective treatment for psoriasis","volume":"70","author":"Levin","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16132","article-title":"Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study","volume":"48","author":"Okubo","year":"2021","journal-title":"J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9076852","article-title":"Risankizumab efficacy in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) remission: A case report on rheumatologic and dermatologic disease manifestations with literature review","volume":"19","author":"Ferraioli","year":"2024","journal-title":"Case Rep Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_353_22","article-title":"Paradoxical SAPHO syndrome after etanercept in a patient with psoriasis","volume":"67","author":"Gimeno-Castillo","year":"2023","journal-title":"Indian J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2050313X251352160","DOI":"10.1177\/2050313x251352160","article-title":"A successful combination of upadacitinib and guselkumab in refractory psoriasis and psoriatic arthritis: A case report","volume":"13","author":"Antolini","year":"2025","journal-title":"SAGE Open Med Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1745464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:41:15Z","timestamp":1771569675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1745464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1745464"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1745464","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1745464"}}